{"filings":[{"id":677516,"accession_number":"0001628280-26-038307","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2026-05-27T11:30:35+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Precision BioSciences reports PBGENE-HBV eliminates cccDNA in biopsies; pgRNA loss in 100% of patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Liver biopsy data show 1-log reduction in cccDNA transcripts after two doses at 0.4 mg/kg; indels inactivate remaining <1%.","pgRNA established as biomarker; 100% of patients (n=6) with detectable pgRNA achieved loss, confirmed by biopsy.","HBsAg declines in 100% of patients (n=15); first patient maintains durable decline for over 12 months.","Safety: No DLTs; manageable LNP-related AEs; mitigation protocol resolved Grade 3 hypotension events with no recurrences.","Next steps: expand enrollment, collect additional biopsies, design Part 2 expansion; update expected by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":670156,"accession_number":"0001628280-26-038220","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2026-05-26T21:20:29+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Precision BioSciences shareholders approve 3.8M share increase for equity plan; elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2019 Incentive Award Plan, increasing share reserve by 3.8M shares (58% for, 42% against).","Amendment to certificate of incorporation approved (17.9M for, 1.4M against) to allow officer exculpation under Delaware law.","Melinda Brown and Geno Germano elected as Class I directors (14.3M and 14.3M votes for respectively).","Ratified Deloitte & Touche as independent auditor for FY2026 (22.2M for, 99k against).","Advisory say-on-pay approved (18.7M for, 613k against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92391,"accession_number":"0001628280-26-030123","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precision BioSciences Q1 net loss $18.4M; cash $125.8M; PBGENE-HBV and PBGENE-DMD trials advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.4M ($0.75/share) vs $20.6M loss ($2.21/share) in Q1 2025.","Revenue $10.8M (vs <$0.1M YoY) driven by $7.5M TG Therapeutics milestone payment for Azer-Cel.","Cash, equivalents, restricted cash $125.8M as of March 31; expected funding through 2028.","PBGENE-HBV: 16 patients treated across 5 cohorts; late-breaking poster accepted at EASL Congress May 27-30.","PBGENE-DMD: FDA IND clearance, Fast Track; first site (Arkansas Children's Hospital) activated, enrolling patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":10838000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103220,"accession_number":"0001628280-26-018397","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Precision BioSciences hosts KOL event for PBGENE-DMD DMD program; no new data disclosed","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["KOL event on March 17, 2026 features Dr. Veerapandiyan and Pat Furlong discussing DMD unmet need and treatment landscape.","Overview of PBGENE-DMD gene editing program and FUNCTION-DMD Phase 1/2 trial presented; no new clinical or financial data released.","Presentation materials and webcast replay available on Precision BioSciences investor website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103219,"accession_number":"0001628280-26-017018","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precision BioSciences Q4 net income $20.1M, PBGENE-HBV shows antiviral activity, cash runway through 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income $20.1M ($1.05 diluted EPS) vs net loss $17.8M YoY; FY net loss $45.7M ($3.56/sh).","Cash, equivalents, restricted cash $137.2M as of Dec 31, 2025; $75M Nov 2025 financing extends runway through 2028.","PBGENE-HBV Phase 1: 13 patients dosed across 5 cohorts; late-breaking data showed safety, dose-dependent antiviral activity and HBsAg declines.","PBGENE-DMD received IND clearance Feb 2026; Fast Track & Orphan Drug designations; initial data from multiple patients expected year-end 2026.","Milestone payments: $8M from Imugene (Oct 2025) and $7.5M from TG Therapeutics (Mar 2026)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103218,"accession_number":"0001628280-26-007114","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","2.02","8.01","9.01"],"status":"ready","headline":"FDA clears Precision BioSciences' IND for PBGENE-DMD gene editing therapy for DMD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Study May Proceed allows initiation of clinical trial site activation for Phase 1/2 FUNCTION-DMD study in ambulatory DMD patients.","PBGENE-DMD is an in vivo gene excision approach targeting mutations in exons 45-55, covering ~60% of DMD patients.","Aims to restore near full-length dystrophin (80% of full-length), larger than existing micro-dystrophin constructs (~34%).","Company plans to activate first US clinical site in the first half of 2026.","Virtual investor event scheduled for March after MDA conference with key opinion leaders and patient advocates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103217,"accession_number":"0001628280-26-001955","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Precision BioSciences reports ~$137M cash, outlines 2026 clinical milestones for HBV and DMD programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash ~$137M as of Dec 31, 2025; cash runway expected through 2028.","PBGENE-HBV: Phase 1/2a ELIMINATE-B dosing Cohorts 3-5 ongoing; additional biopsy data expected H1 2026.","PBGENE-DMD: IND clearance expected Q1 2026; first patient dosing late-Q1/early-Q2 2026; initial data by year-end 2026.","Partnered programs: iECURE ECUR-506 RMAT designation; Imugene milestone $8M received; TG Therapeutics potential $7.5M milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119466,"accession_number":"0001628280-25-051382","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Precision BioSciences prices $75M underwritten offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering: 10.8M shares + 1.4M pre-funded warrants at $6.14/$6.139995 per unit; gross proceeds ~$75M.","Net proceeds ~$70M after discounts and expenses, expected close Nov 12, 2025.","Each whole warrant exercises at $7.25/share, 5-year term; 4.99% beneficial ownership cap applies.","Proceeds to fund R&D for ARCUS gene editing pipeline and working capital.","Guggenheim Securities sole book-runner; participation from Aberdeen, Bleichroeder, Driehaus, and others."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119465,"accession_number":"0001628280-25-051168","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Precision BioSciences reports positive Phase 1 PBGENE-HBV data; first human biopsy evidence of viral gene editing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 ELIMINATE-B trial: 9 patients across 0.2, 0.4, 0.8 mg/kg doses (22 total administrations); no dose-limiting toxicities observed.","All patients showed HBsAg reductions; Cohort 3 (0.8 mg/kg) had steep early declines with cumulative effect – one patient achieved 64% decrease.","Paired liver biopsy from Cohort 2 confirmed ARCUS-mediated indel edits in HBV DNA – first direct human evidence of viral gene editing.","Transient infusion reactions and asymptomatic platelet fluctuations; one reversible Grade 3 AST elevation resolved within 3 days.","Cohort 3 dosing to complete Q1 2026; next step: Part 2 expansion with optimized regimen and mandatory paired biopsies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119464,"accession_number":"0001628280-25-047920","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precision BioSciences Q3 net loss $21.8M ($1.84/sh); PBGENE-HBV doses Cohort 3, PBGENE-DMD IND on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.8M ($1.84/sh) vs $16.4M ($2.25/sh) in Q3 2024.","Revenue <$0.1M, down from $0.6M YoY; R&D $13.4M, G&A $7.3M.","Cash $71.2M; expected runway into H2 2027 via cost cuts and potential near-term CAR T payments.","PBGENE-HBV Phase 1 dosing Cohort 3; late-breaking oral at AASLD on Nov 10.","PBGENE-DMD IND filing expected end-2025; Phase 1 start H1 2026, initial data H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":60000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136032,"accession_number":"0001357874-25-000005","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Precision BioSciences amends employment agreements with four top executives; adds escrow for severance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended agreements with CEO Michael Amoroso, CFO Alex Kelly, GC Dario Scimeca, and CRO Jeff Smith.","Changes include current base salary, target bonus, lump-sum cash severance, and change-in-control/restructuring provisions.","Cash severance and expenses must be funded in an escrow account with JPMorgan Chase; interest accrues to company.","Unused funds return to Precision BioSciences; agreements are substantively similar to prior contracts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136031,"accession_number":"0001628280-25-038592","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precision BioSciences Q2 net loss $23.5M; HBV gene editing shows HBsAg reduction in all patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.5M ($2.13 per share) vs net income $32.7M a year ago; revenue less than $0.1M (prior $49.9M on non-cash revenue).","Phase 1 ELIMINATE-B trial: PBGENE-HBV showed 47-69% HBsAg reduction in all 3 Cohort 1 patients; one patient had durable ~50% reduction at 7 months.","Cohort 2 safety data showed no Grade>2 AEs; DMC recommended enrolling Cohort 3. Cash runway extended to H2 2027 via operating cost cuts of ~$25M/year.","PBGENE-DMD: FDA granted Rare Pediatric Disease and Orphan Drug designations; IND/CTA filing targeted by end of 2025 with clinical data in 2026.","Total operating expenses fell $3.9M YoY to $21.9M; cash and equivalents $84.8M as of June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":47000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136030,"accession_number":"0001628280-25-038094","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Precision BioSciences' PBGENE-HBV shows durable HBsAg reduction in Phase 1; cash runway to H2 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cohort 1 (0.2 mg/kg): well-tolerated; best HBsAg reductions of 56%, 69%, and 47% across three patients.","Patient 1 maintained ~50% HBsAg reduction 7 months after initial dose, indicating durable antiviral editing.","Cohort 2 (0.4 mg/kg) shows no Grade 3+ AEs; DMC approved escalation to Cohort 3.","Cash runway extended to H2 2027 via ~$25M annual operating expense reduction program starting July 2025.","Dr. Mark Sulkowski appointed Head Clinical Development Advisor for PBGENE-HBV and later-stage trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153063,"accession_number":"0000950170-25-080564","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Precision BioSciences' charter amendment for officer exculpation fails at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Kevin J. Buehler and Shari Lisa Piré elected as Class III directors.","Deloitte & Touche ratified as auditor (7,445,447 FOR, 12,604 against).","Advisory say-on-pay approved; board sets frequency at every 1 year.","Proposal for officer exculpation amendment failed: ~3.5M FOR votes (95% of cast) but not >50% of outstanding shares, largely due to 3.75M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153062,"accession_number":"0000950170-25-072016","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Precision BioSciences Q1 net loss $20.6M; revenue drops to <$0.1M; PBGENE-DMD accelerated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue less than $0.1M vs $17.6M in Q1 2024; net loss of $20.6M ($2.21/share) vs net income $8.6M ($1.70/share) a year ago.","Cash, equivalents and restricted cash ~$100M; cash runway expected into H2 2026, funding PBGENE-HBV and PBGENE-DMD through Phase 1 data.","PBGENE-HBV cleared for U.S. Phase 1 (FDA IND) and UK (MHRA); Fast Track designation granted; initial safety data presented at EASL.","PBGENE-DMD prioritized as second wholly owned program; IND/CTA target in 2025 with clinical data expected in 2026.","PBGENE-3243 development paused to focus resources on HBV and DMD programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":29000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153061,"accession_number":"0000950170-25-071551","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Precision BioSciences accelerates PBGENE-DMD, plans IND/CTA in 2025; pauses PBGENE-3243","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PBGENE-DMD is a first-in-class in vivo gene editing approach targeting exons 45-55; up to 60% of DMD patients carry mutations in this hotspot region.","Preclinical data shows durable functional improvement in a humanized DMD mouse model over 9 months with restored dystrophin expression.","Precision targets to file IND/CTA for PBGENE-DMD in 2025, with clinical data expected in 2026.","Company pauses development of PBGENE-3243 (m.3243 mitochondrial disease) to prioritize PBGENE-DMD and HBV; cash runway sufficient for both through Phase 1.","PBGENE-DMD preclinical data presented at ASGCT Annual Meeting on May 14, 2025; webcast held May 15."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171845,"accession_number":"0000950170-25-044764","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precision BioSciences FY2024 net income $7.2M; PBGENE-HBV Phase 1 shows HBsAg reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $17.8M ($2.22/sh) vs $16.3M loss in Q4 2023; FY2024 net income $7.2M vs FY2023 loss $61.3M.","Cash, equivalents $108.5M at Dec 31, 2024; cash runway expected into H2 2026.","PBGENE-HBV Phase 1 low-dose cohort (N=3) dosed; well-tolerated with no grade ≥2 AE; 2 of 3 patients showed substantial HBsAg reduction.","Partner iECURE reported complete clinical response in first infant dosed for OTC deficiency; ECUR-506 generally well tolerated.","Appointed Cindy Atwell as Chief Development and Business Officer and Dr. Cassie Gorsuch as Chief Scientific Officer in Jan 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171844,"accession_number":"0000950170-25-035562","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Precision BioSciences reshuffles director classes, cuts board to six members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board reclassified Michael Amoroso from Class I to Class II director.","Melinda Brown reclassified from Class III to Class I director.","Board size reduced from seven to six directors effective March 4, 2025.","Changes follow prior resignation of Sam Wadsworth from the Board.","No disagreements cited; committee assignments unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171843,"accession_number":"0000950170-25-010209","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Sam Wadsworth retires from Precision BioSciences board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sam Wadsworth, Ph.D., resigned from Board of Directors effective January 23, 2025.","Resignation is not due to any disagreement with company operations, policies, or practices.","No replacement was named; board size decreased by one."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171842,"accession_number":"0000950170-25-003290","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Precision BioSciences reports $108.5M preliminary cash; receives $2.5M from TG Therapeutics, issues shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, cash equivalents, and restricted cash of ~$108.5M as of Dec 31, 2024, before $2.5M TG payment in Jan 2025.","Expects cash runway into second half of 2026, sufficient to fund two wholly owned programs through Phase 1 data readouts.","On Jan 6, 2025, received $2.5M deferred cash payment from TG Subsidiary and issued 220,712 shares of common stock.","The payment and shares relate to the January 2024 License Agreement for non-oncology applications of allogeneic CAR T therapy azer-cel.","These estimates are preliminary and subject to audit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188846,"accession_number":"0000950170-24-120278","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precision BioSciences Q3 revenue $0.6M, net loss $16.4M; PBGENE-HBV enters clinic","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $0.6M down from $13.1M YoY; net loss $16.4M ($2.25/share) vs $8.1M loss in Q3 2023.","Cash $121.3M sufficient into H2 2026, supplemented by $22.5M loan from Banc of California (maturing June 2027).","PBGENE-HBV CTA approved in Moldova; patient screening underway; Phase 1 data expected in 2025.","PBGENE-3243 (mitochondrial disease) IND/CTA expected in 2025; regained rights to three Prevail programs under assessment.","Appointed Dr. Murray Abramson SVP Head of Clinical Development and John Fry as Strategic Clinical Advisor for hepatitis."],"consensus_eps_estimate":null,"consensus_eps_actual":3.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":68058000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188845,"accession_number":"0000950170-24-116864","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Precision BioSciences reports ~$121M cash, gets first CTA approval for PBGENE-HBV in Moldova","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Expected cash, cash equivalents, and restricted cash of ~$121M as of Sept 30, 2024 (preliminary, unaudited).","Received CTA approval in Moldova for PBGENE-HBV, a first-in-human in vivo gene editing study for chronic hepatitis B.","PBGENE-HBV targets and eliminates cccDNA and inactivates integrated HBV DNA, aiming for functional cure.","Company to host investor event on Nov 15, 2024 prior to AASLD meeting to share preclinical safety package and Phase 1 trial details.","Additional global CTA and IND submissions underway to accelerate patient enrollment across multiple sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205325,"accession_number":"0000950170-24-105706","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Precision BioSciences names Murray Abramson SVP Clinical Development, John Fry as HBV Advisor; CMO List retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alan List, CMO, retiring effective Sept 13, 2024; will transition to clinical consultant at $325/hour and remain on SAB.","Murray Abramson, MD MPH, appointed SVP Head of Clinical Development; previously SVP at Tempus, VP at Biogen, roles at Merck.","John Fry appointed Strategic Clinical Advisor for hepatitis; former EVP at Aligos Therapeutics, Head Early Development at Alios.","Leadership changes strengthen team for PBGENE-HBV (hepatitis B) with anticipated Phase 1 data milestones in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205324,"accession_number":"0000950170-24-102561","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Precision BioSciences receives $9.75M cash + $3.25M Imugene shares from convertible note maturity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Convertible note from August 2023 azer-cel deal with Imugene matured; Precision receives $9.75M cash and $3.25M in Imugene ordinary shares.","Cash injection extends expected runway into second half of 2026; Q2 2024 cash balance was ~$123.6M before this receipt.","Company on track to file applications for PBGENE-HBV (chronic hepatitis B) with multiple global regulators later in 2024.","Precision expects to generate Phase 1 clinical data across multiple in vivo gene editing programs starting first half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205323,"accession_number":"0000950170-24-088950","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precision BioSciences Q2 2024 net income $32.7M; cash $123.6M; HBV program on track for IND in 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income from continuing ops $32.7M vs loss $11.9M YoY; revenue $49.9M (+$30.1M) from Prevail termination.","Cash $123.6M; expected runway into H2 2026.","PBGENE-HBV on track for IND/CTA submission in 2024; PBGENE-PMM targeted for 2025.","Regained control of three preclinical programs from Prevail (DMD, liver, CNS) for internal/partner development.","Entered into $22.5M term loan with Banc of California (maturity June 2027)."],"consensus_eps_estimate":null,"consensus_eps_actual":6.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":67482000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222219,"accession_number":"0000950170-24-071082","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Precision BioSciences shareholders approve increase of 630,000 shares in incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected Stanley R. Frankel, M.D. and Samuel Wadsworth, Ph.D. as Class II directors for term until 2027.","Ratification of Deloitte & Touche as independent auditor for FY2024 approved with 5,162,463 votes for.","Amendment to 2019 Incentive Award Plan approved, increasing share reserve by 630,000 shares; 2,597,767 for, 836,298 against.","Adjournment proposal approved with 2,649,161 votes for, if needed to solicit additional proxies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222218,"accession_number":"0000950170-24-058191","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precision BioSciences Q1 2024 revenue $17.6M, net income $8.6M; cash runway into H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $17.6M (up from $8.8M YoY); net income $8.6M vs loss $25.1M in Q1 2023.","Cash and equivalents $137.8M; cash runway extended into H2 2026 via $40M equity offering.","PBGENE-HBV on track for IND/CTA filing in 2024; PBGENE-PMM expected in 2025.","iECURE's OTC gene editing program opened enrollment in UK, first in vivo ARCUS trial.","Regained rights to three preclinical programs (DMD, liver, CNS) from Prevail collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":1.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":17584000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222217,"accession_number":"0000950170-24-055089","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Precision BioSciences sells 25,000 shares at $12 to management in private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$300k from sale of 25,000 shares at $12.00/share (13.5% premium to prior day close).","CEO Michael Amoroso and CFO Alex Kelly each purchase 8,334 shares ($100k); GC and CRO purchase 833 shares each.","Net proceeds to be used to fund ongoing research and development initiatives; close expected May 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222216,"accession_number":"0000950170-24-044831","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["1.02","2.02","7.01","9.01"],"status":"ready","headline":"Precision BioSciences loses Lilly/Prevail collaboration; regains DMD, PBGENE-LLY2, PBGENE-LLY3 programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prevail (Lilly sub) terminated collaboration without cause effective July 10, 2024; Precision exercised reversion option to regain programs.","Collaboration had generated up to $135M upfront; potential milestones up to $390-395M per product plus royalties are now lost.","Preliminary Q1 2024 cash ~$137M; expected cash runway into H2 2026 unaffected (no Prevail milestones assumed).","Precision claims strong proof-of-concept data: up to 45% gene insertion in non-dividing cells in NHP; plans to develop programs independently or with new partners.","Near-term priorities (HBV, PMM, OTC partnership with iECURE) unchanged; IND/CTA submissions on track for 2024-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241735,"accession_number":"0000950170-24-036816","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precision BioSciences reports FY 2023 net loss of $61.3M; extends cash runway into H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2023 revenue $48.7M (up from $25.1M in 2022); loss from continuing ops $42.5M.","Cash $116.7M at Dec 31, 2023; recent $40M public offering and CAR T licensing deals add ~$50M.","Completed licensing deals with Imugene, TG Therapeutics, and Caribou; total upfront/near-term ~$50M.","PBGENE-HBV IND/CTA submission planned in 2024; PBGENE-PMM submission in 2025.","Net loss per diluted share $(15.96) vs $(38.10) in FY 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241734,"accession_number":"0001104659-24-029636","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Precision BioSciences prices $40M public offering of 2.5M shares and warrants at $16/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 2,500,000 common shares and warrants to purchase another 2,500,000 shares at $16.00 per unit.","Warrants have $20.00 exercise price, are immediately exercisable, and expire in 5 years.","Gross proceeds of $40.0M; net proceeds estimated at ~$37.1M after underwriting discounts.","Proceeds to fund R&D and general corporate purposes; closing expected March 5, 2024.","Participants include Perceptive Advisors, Janus Henderson, Aquilo Capital, LYFE Capital; Guggenheim sole book-runner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241733,"accession_number":"0000950170-24-014194","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Precision BioSciences effects 1-for-30 reverse stock split effective Feb 13, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-30 ratio effective 5:00 p.m. ET on February 13, 2024.","Every 30 pre-split shares reclassified into 1 share; fractional shares paid in cash.","Cash payment for fractions based on closing price of DTIL on Nasdaq on Feb 13, 2024.","Split-adjusted trading begins Feb 14 under same symbol DTIL; new CUSIP 74019P207.","Authorized shares and par value unchanged; split approved by stockholders Jan 18 and Board Feb 6."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241732,"accession_number":"0000950170-24-006661","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2024-01-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Precision BioSciences enters new exec employment agreements with enhanced severance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Michael Amoroso: 18-month salary severance, 1.5x target bonus, 25-month equity acceleration.","CFO Alex Kelly, GC Dario Scimeca, CRO Jeff Smith: 12-month salary severance, 1x target bonus, 13-month equity acceleration.","Enhanced COBRA premium reimbursement and extended option exercise periods for all four executives.","Agreements effective Jan 22, 2024, supersede prior employment agreements from September 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241731,"accession_number":"0000950170-24-005581","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Precision BioSciences stockholders approve reverse split; board authorized to set ratio 1-for-10 to 1-for-30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approximately 68.34% of common shares represented at special meeting on January 18, 2024.","Proposal 1 passed: 71,771,593 votes for (86.1%), 11,275,251 against, 281,803 abstain.","Board has discretion to fix the reverse split ratio between 1-for-10 and 1-for-30 and may abandon the amendment.","Adjournment proposal also passed (75.3M for) but was not needed as Proposal 1 received sufficient votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241730,"accession_number":"0000950170-24-003761","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","9.01"],"status":"ready","headline":"Precision BioSciences licenses azer-cel to TG Therapeutics for $17.5M upfront, up to $288M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Precision grants TG Therapeutics exclusive license for non-oncology applications of azer-cel, receiving $17.5M in upfront and near-term payments.","TG Therapeutics to purchase 2,920,816 shares of Precision common stock at $0.77 per share, a 100% premium to 30-day VWAP.","Precision expects $116M cash as of Dec 31, 2023; combined with deal payments extends cash runway into first half 2026.","Potential milestone payments up to $288.6M and tiered royalties from mid-single to low-double digit on net sales.","License covers autoimmune diseases and other non-oncology indications; Precision retains oncology rights with Imugene."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259180,"accession_number":"0000950170-23-072457","cik":1357874,"company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Precision BioSciences amends bylaws for universal proxy and nomination procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted amended bylaws on Dec 19, 2023, effective same day, addressing SEC universal proxy rules.","New rules require compliance with Rule 14a-19 for proxy solicitations supporting non-Board nominees.","Enhanced disclosure requirements for stockholder nominations and proposals, including derivative interests.","Prohibits stockholders from submitting more director nominees than seats up for election.","Requires proxy cards for dissident solicitations to be a color other than white."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":183324962.37944666,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}